Saudi FDA Grants Accelerated Approval to ImmunityBio's ANKTIVA® In Combination with Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer

Core Viewpoint - ImmunityBio, Inc. has received accelerated approval from the Saudi Food and Drug Authority for ANKTIVA® in combination with immune checkpoint inhibitors for treating adult patients with metastatic non-small cell lung cancer who have progressed after standard therapy [1] Group 1 - The approval of ANKTIVA® represents a significant milestone as it is the first approval of this treatment in the region [1] - The indication is specifically for adult patients with metastatic non-small cell lung cancer (NSCLC) whose disease has progressed following standard-of-care therapy [1]